Effects of recombinant human erythropoietin on blood pressure and renal function in SHR with chronic renal failure.
1. The effects of chronic administration of erythropoietin (EPO) on blood pressure and renal function in rats with ablation of renal mass were assessed. 2. Spontaneously hypertensive rat were subjected to 5/6 nephrectomy (5/6Nx). Four weeks after the operation, the rats were randomly allocated to vehicle, EPO 20IU/kg i.p., or EPO 100 IU/kg i.p. (both given twice a week) for 4 weeks. 3. Marked anaemia was noted in SHR-5/6Nx. EPO caused a significant increase in haematocrit at a high dose but not at a low dose. A dose dependent relationship was noted in the EPO-induced rise in the systolic blood pressure. 4. EPO dose-dependently increased urinary protein excretion. It also increased blood urea nitrogen and serum creatinine levels. 5. These results suggest that EPO ameliorates anaemia and severely accelerates renal failure in SHR-5/6Nx. They also suggest that anaemia can be a haemodynamically favorable adaptation to chronic renal disease and that its correction may have adverse renal haemodynamic and structural consequences.
Kohzuki
M
M
Section of Internal Medicine and Disability Prevention, Tohoku University Graduate School, Sendai, Japan.
Yasujima
M
M
Kanazawa
M
M
Yoshida
K
K
Sato
T
T
Abe
K
K
D000740:Anemia / Q000503:physiopathology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology*; D007677:Kidney Function Tests; D009392:Nephrectomy; D051381:Rats; D011918:Rats, Inbred SHR; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D004921:Erythropoietin